Potential effects include injectionsite irritation, fluid retention, joint aches, tingling, changes in blood sugar or lipids, and shifts in IGF1
Every patient receives bloodwork before any GLP-1 medication is prescribed, with no exceptions
For type 2 diabetes, semaglutide is an approved treatment at the doses found in Ozempic
Among these, three pivotal studies demonstrated particularly noteworthy results: The LEADER trial evaluated liraglutide (1.8 mg/day subcutaneous) in 9,340 patients, establishing a foundation for cardiovascular risk reduction with GLP-1 therapy [2]
Its unsettling to notice, but its typically short-lived and reversible
Growth hormone secretagogue receptor dimers: A new pharmacological target